玻璃体内注射贝伐单抗（阿瓦斯汀）作为眼部弓形虫病继发脉络膜新生血管的一线及挽救治疗。
Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis.
作者信息
Ben Yahia Salim, Herbort Carl P, Jenzeri Salah, Hmidi Kamel, Attia Sonia, Messaoud Riadh, Khairallah Moncef
机构信息
Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir 5019, Tunisia.
出版信息
Int Ophthalmol. 2008 Aug;28(4):311-6. doi: 10.1007/s10792-008-9218-2. Epub 2008 Apr 10.
BACKGROUND
Treatment modalities for choroidal neovascularization due to ocular toxoplasmosis include laser photocoagulation, surgery, corticosteroids, and verteporfin therapy. Intravitreal injection of bevacizumab in the treatment of choroidal neovascularization due to other conditions appears to be an effective and safe therapeutic option.
CASE REPORTS
We report two young patients with choroidal neovascularization secondary to ocular toxoplasmosis who received a single intravitreal injection of bevacizumab as primary or rescue therapy. After a follow-up of 12 and 10 months, respectively, visual acuity improved, and features of active neovascularization resolved with no recurrence. No adverse events were recorded.
CONCLUSION
Intravitreal injection of bevacizumab appears to be an effective and safe treatment modality in patients with choroidal neovascularization secondary to ocular toxoplasmosis. Further evaluation with a longer follow-up period is needed to confirm these findings.
背景
眼部弓形虫病所致脉络膜新生血管的治疗方式包括激光光凝、手术、皮质类固醇和维替泊芬治疗。玻璃体内注射贝伐单抗用于治疗其他原因所致脉络膜新生血管似乎是一种有效且安全的治疗选择。
病例报告
我们报告了两名继发于眼部弓形虫病的脉络膜新生血管年轻患者，他们接受了单次玻璃体内注射贝伐单抗作为初始或挽救治疗。分别随访12个月和10个月后，视力改善，活动性新生血管特征消退且无复发。未记录到不良事件。
结论
玻璃体内注射贝伐单抗似乎是继发于眼部弓形虫病的脉络膜新生血管患者的一种有效且安全的治疗方式。需要更长随访期的进一步评估来证实这些发现。
Zotero 插件